RNA Interference (RNAi) Drug Delivery Market Report by Application (Infectious Disease, Cardiology, Oncology, Neurology, Ophthalmology, Urology, Metabolic Disorders, and Others), Technology (Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery, Aptamer Drug Delivery), and Region 2026-2034

RNA Interference (RNAi) Drug Delivery Market Report by Application (Infectious Disease, Cardiology, Oncology, Neurology, Ophthalmology, Urology, Metabolic Disorders, and Others), Technology (Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery, Aptamer Drug Delivery), and Region 2026-2034

Report Format: PDF+Excel | Report ID: SR112026A2758

Market Overview:

The global RNA interference (RNAi) drug delivery market size reached USD 117.5 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 504.2 Billion by 2034, exhibiting a growth rate (CAGR) of 17.04% during 2026-2034.

Report Attribute 
Key Statistics
Base Year
2025
Forecast Years
2026-2034
Historical Years
2020-2025
Market Size in 2025
USD 117.5 Billion
Market Forecast in 2034
USD 504.2 Billion
Market Growth Rate (2026-2034) 17.04%

Ribonucleic acid interference (RNAi) drug delivery refers to a therapeutic solution to monitor gene expression or mutations. RNAi drug delivery is usually administered through intravenous, intra-dermal and intraperitoneal injections and topical delivery methods. It involves nanoparticle, pulmonary, nucleic acid and aptamer drug delivery technologies. These technologies are also used for analyzing gene functions in eukaryotes and developing therapeutic gene silencing solutions. As a result, RNAi drug delivery is widely used for treating infectious diseases, chronic metabolic disorders, cardiovascular, neurological, urological, oncological and ophthalmological disorders.

RNA Interference (RNAi) Drug Delivery Market Size

To get more information on this market Request Sample

The increasing prevalence of chronic medical and genetic disorders, such as cancer and cardiovascular diseases (CVDs) across the globe, represents one of the key factors driving the growth of the market. Furthermore, the rising geriatric population, which is more susceptible to such ailments, is also driving the market growth. In line with this, as the coronavirus disease (COVID-19) continues to spread across the globe, there has been a significant increase in the demand for RNAi drug delivery technologies. Targeted delivery methods, such as aptamer drug delivery systems, are gaining immense traction for the administration of antiviral drugs as they are induced by small interfering RNA (siRNA) that can inhibit the expression of viral antigens. Additionally, various technological advancements, such as the development of innovative synthetic delivery carriers and bio-vectors, are anticipated to drive the market growth. The nanocarriers, including siRNA or microRNAs (miRNA), are crucial for developing personalized medicines and identifying altered cellular molecules and metabolites. Other factors, including extensive research and development (R&D) activities in the fields of nanotechnology and molecular diagnostics, along with overall improvements in the healthcare infrastructure, are anticipated to drive the market further.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global RNA interference (RNAi) drug delivery market report, along with forecasts at the global, regional and country level from 2026-2034. Our report has categorized the market based on application and technology.

Breakup by Application:

RNA Interference (RNAi) Drug Delivery Market By Application

Access the comprehensive market breakdown Request Sample

  • Infectious Disease
  • Cardiology
  • Oncology
  • Neurology
  • Ophthalmology
  • Urology
  • Metabolic Disorders
  • Others
     

Breakup by Technology:

  • Nanoparticle Drug Delivery
  • Pulmonary Drug Delivery
  • Nucleic Acid Drug Delivery
  • Aptamer Drug Delivery
     

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa
     

Competitive Landscape:

The report provides a comprehensive analysis of the competitive landscape in the global RNA interference (RNAi) drug delivery market with detailed profiles of all major companies, including:

  • Alnylam Pharmaceuticals, Inc.
  • Arrowhead Pharmaceuticals, Inc.
  • Calando Pharmaceuticals Inc
  • Ionis Pharmaceuticals, Inc.
  • Phio Pharmaceuticals
  • Silence Therapeutics
  • Sirnaomics
  • Switch Therapeutics

Report Coverage:

Report Features Details
Base Year of the Analysis 2025
Historical Period 2020-2025
Forecast Period 2026-2034
Units Billion USD
Segment Coverage Application, Technology, Region
Regions Covered Asia Pacific, Europe, North America, Latin America, Middle East and Africa
Countries Covered United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
Companies Covered Alnylam Pharmaceuticals, Inc., Arrowhead Pharmaceuticals, Inc., Calando Pharmaceuticals Inc, Ionis Pharmaceuticals, Inc., Phio Pharmaceuticals, Silence Therapeutics, Sirnaomics, Switch Therapeutics, etc.
Customization Scope 10% Free Customization
Post-Sale Analyst Support 10-12 Weeks
Delivery Format PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)

Frequently Asked Questions About the RNA Interference (RNAi) Drug Delivery Market Report

The RNA interference drug delivery market was valued at USD 117.5 Billion in 2025.

The RNA interference drug delivery market is projected to exhibit a CAGR of 17.04% during 2026-2034, reaching a value of USD 504.2 Billion by 2034.

The RNA interference drug delivery market is driven by advances in delivery technologies enhancing drug stability and targeting, growing prevalence of chronic diseases, and increased government funding for RNAi research. Rising investments, strategic collaborations, and successful regulatory approvals also fuel market growth, supporting the development of innovative, personalized RNAi therapies.

North America currently dominates the RNA interference drug delivery market, driven by a strong biotechnology sector, advanced healthcare infrastructure, and supportive regulatory frameworks. High R&D investment, strategic collaborations, and growing demand for targeted therapies contribute to market growth. The presence of major pharmaceutical players also accelerates RNAi innovation and commercialization.

Some of the major players in the RNA interference drug delivery market include Alnylam Pharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., CureVac AG, Dicerna Pharmaceuticals Inc., Gradalis Inc., Ionis Pharmaceuticals Inc, Merck & Co. Inc., Moderna Inc., Quark Pharmaceuticals Inc. (SBI ALApharma Co. Limited), Silence Therapeutics Plc, Sirnaomics Inc, etc.

Need more help?

  • Speak to our experienced analysts for insights on the current market scenarios.
  • Include additional segments and countries to customize the report as per your requirement.
  • Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
  • For further assistance, please connect with our analysts.
RNA Interference (RNAi) Drug Delivery Market Report by Application (Infectious Disease, Cardiology, Oncology, Neurology, Ophthalmology, Urology, Metabolic Disorders, and Others), Technology (Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery, Aptamer Drug Delivery), and Region 2026-2034
Purchase Options Discount
Offer
Benefits of Customization
  • Personalize this research
  • Triangulate with your data
  • Get data as per your format and definition
  • Gain a deeper dive into a specific application, geography, customer, or competitor
  • Any level of personalization

Get in Touch With Us

UNITED STATES

Phone: +1-201-971-6302

INDIA

Phone: +91-120-433-0800

UNITED KINGDOM

Phone: +44-753-714-6104

Email: [email protected]

Client Testimonials